US 11,746,105 B2
Bryostatin compounds and methods of preparing the same
Paul Wender, Stanford, CA (US); Ryan Quiroz, Boston, MA (US); Stephen Ho, Stanford, CA (US); Akira Shimizu, Stanford, CA (US); Steven Ryckbosch, Albany, CA (US); Matthew C. Stevens, Atherton, CA (US); Matthew S. Jeffreys, King of Prussia, PA (US); Clayton Hardman, Stanford, CA (US); and Jack Sloane, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Jan. 29, 2021, as Appl. No. 17/162,554.
Application 17/162,554 is a division of application No. 16/337,221, granted, now 10,947,221, previously published as PCT/US2017/054158, filed on Sep. 28, 2017.
Claims priority of provisional application 62/404,687, filed on Oct. 5, 2016.
Prior Publication US 2021/0292309 A1, Sep. 23, 2021
Int. Cl. C07D 407/14 (2006.01); A61K 31/351 (2006.01); A61P 25/28 (2006.01); A61P 31/18 (2006.01); C07D 493/22 (2006.01); A61P 35/00 (2006.01); A61K 31/365 (2006.01)
CPC C07D 407/14 (2013.01) [A61K 31/351 (2013.01); A61K 31/365 (2013.01); A61P 25/28 (2018.01); A61P 31/18 (2018.01); A61P 35/00 (2018.01); C07D 493/22 (2013.01)] 3 Claims
 
1. A bryostatin analog having the formula (XXXI):

OG Complex Work Unit Chemistry
wherein:
R4 is an alkyl or a substituted alkyl;
Z2 is CR5R6 or NR7 when the covalent bond designated “b” is a double bond;
Z2 is OR8 or N(R7)2 when the covalent bond designated “b” is a single bond;
R5 is alkyloxycarbonyl, substituted alkyloxycarbonyl, alkyl or substituted alkyl;
R6, R7 and R8 are each independently H, alkyloxycarbonyl, substituted alkyloxycarbonyl, alkyl or substituted alkyl;
R11 is a substituted acyl, an alkyl or a substituted alkyl;
R12 is H, an alkyl or a substituted alkyl;
R13 is H, an alkyl or a substituted alkyl; and
R14 and R15 are independently H, a hydroxyl protecting group or a promoiety;
or a solvate, hydrate or prodrug form thereof and/or a salt thereof.